-
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Tuesday, August 30, 2016 - 12:16pm | 552Read More...Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...
-
Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex
Tuesday, October 20, 2015 - 12:00pm | 622Read More...Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...
-
Goldman Comments On Vertex Pharmaceuticals Following FDA Approval
Thursday, July 2, 2015 - 1:41pm | 242Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) were trading higher by nearly 4 percent on Thursday after the FDA approved the company's Orkambi (lumacafor/ivacaftor) for the treatment of cystic fibrosis patients 12 years and older. Commenting on the FDA's approval, Terence Flynn, PhD...
-
Maxim: Our Vertex Pharma Thesis Is Unchanged
Friday, March 20, 2015 - 11:29am | 291Read More...In a report published Friday, Maxim Group analyst Jason Kolbert said that his thesis on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) remains unchanged for the following reasons: Kalydeco (ivafcaftor) has been approved for children with one of ten gating/conductance mutations, adding an...
-
JP Morgan Buyer on Vertex Pharmaceuticals' Weakness
Thursday, June 28, 2012 - 10:45am | 137Read More...JP Morgan has published a research report on Vertex Pharmaceuticals (NASDAQ: VRTX) following up on Kalydeco + VX-809 on Cystic Fibrosis. In the report, JP Morgan writes, "[We] are buyers on weakness today given that the final phase 2 data is clearly de-risking in the homozygous F508del CF...
